Why the study?
Neuroleptic malignant syndrome is a dangerous complication of neuroleptic therapy with high mortality, but existing publications are primarily review articles or case reports.
NMS remains a rare (0.035%) but highly dangerous complication of antipsychotic therapy with a 10.5% mortality rate, occurring with both first- and second-generation antipsychotics.
No takes yet. Share an insight, caveat, or question.
Clinicians should sustain NMS vigilance in antipsychotic therapy; Level 4 data leaves open prospective risk-factor studies.
Dmitry Malin (2023) studied this question.